Research solutions

Sample to Insight COVID-19 wastewater testing

There's growing evidence that successful detection of SARS-CoV-2 RNA in wastewater or natural sewage is a powerful surveillance tool to prevent a surge in COVID-19 infections, and specifically of new variants that are gaining ground in certain communities. QIAGEN supports wastewater-based epidemiology efforts with research tools spanning nucleic acid extraction, amplification and detection, overcoming some of the common challenges with the analytical protocols along the workflow.

Rapid genotyping of SARS-CoV-2 variants of concern

A number of concerning lineages classified as VOCs are associated with either higher transmissibility, virulence or ability to evade the immune response gained through prior infection or vaccination. The mutations in the viral genome of these variants are associated with change in 'fitness' or are unique to their lineage and can therefore be used as genetic markers for genotyping. It allows discriminating from the wild-type strain or other variants. Confronting these new variants demands constant surveillance and accelerated development of innovative early-detection tools.

Innovative PCR solution for epidemiological research

The QIAprep&amp Viral RNA UM Kit is an innovative, liquid-based approach to viral RNA epidemiology. In one streamlined kit, it combines a two-minute sample preparation with RT-qPCR detection that takes under one hour to generate data. With a simple, three-step workflow, with the possibilities for automation, this kit can significantly accelerate the turnaround time and frequency for epidemiological research.

Pyrosequencing for COVID-19 genotyping

The prevalence of variants must be rapidly detected and reported to keep pace with the mutating SARS-CoV-2 virus. NGS is the current gold standard for genotyping of SARS-CoV-2; however, it is not feasible to genotype samples in real-time on a population-wide scale. RT-qPCR assays could provide an alternative approach that supplements NGS surveillance activities with its ability to genotype all SARS-CoV-2 cases on the day that it is detected. However, it is time-consuming to develop new assays for each emerging mutation, leading to potential delays in surveillance. The Pyrosequencing method presents a cost-effective solution and makes it easier to design new assays for emerging variants.

Whole genomic sequencing services

QIAGEN Genomic Services provides a comprehensive Sample-to-Insight SARS-CoV-2 Whole Genome Sequencing Services to support your research. Whether you’re studying strain evolution or performing phylogeographic or metagenomic analyses, Genomic Services is the right partner for providing impactful insights and helping accelerate your COVID-19 research. This service uses technology especially designed for SARS-CoV-2 research.

Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights

To support the efforts of clinical microbiology and public health laboratories involved in SARS-CoV-2 sequencing, QIAGEN offers free temporary licenses to QIAGEN CLC Genomics and QIAGEN Ingenuity Pathway Analysis (IPA) bioinformatics software. In addition, until June 30, 2021 we are offering labs that purchase the QIAseq SARS-CoV-2 Primer Panel Kit (96) a 25% discount off any 1-year subscription to QIAGEN CLC Genomics bioinformatics software.

Additionally, our data scientists have expanded upon recent peer-reviewed research to generate relevant SARS-CoV-2 protein networks. This freely available Coronavirus Network Explorer helps you visualize how SARS-CoV-2 proteins interact with human host proteins to disable protective responses and pathways, and explore hypotheses around ways to fight coronavirus. 

Maximize insights from SARS-CoV-2 T cell immune response

T cells are increasingly recognized for their role in SARS-CoV-2 infection and immunity, and the exploration of immune response markers during COVID-19 infection is becoming the next tool for researching potential improvements in patient management and vaccination guidance in the future.

The QuantiFERON SARS-CoV-2 RUO solution uses a combination of antigens specific to SARS-CoV-2 to stimulate lymphocytes in heparinized whole blood. Plasma from the stimulated samples can be used for detection of cytokines, including IFN-γ.

Tailored oligonucleotides for SARS-CoV-2 detection

In our effort to support the detection of the SARS-CoV-2 virus, OEM by QIAGEN has ramped up the production of SARS-CoV-2 specific primers and probes. We provide customized oligos defined by our customers, as well as those mentioned in protocols recommended by WHO and the CDC. To meet the high demands, we are currently prioritizing the orders of SARS-CoV-2 specific oligonucleotides. In addition, we have introduced pre-manufacturing of these oligonucleotides to enable quick supply and delivery. To order please send your requests here.